Follicular Lymphoma Market
The Follicular Lymphoma market is on a strong upward trajectory, with the market size across the 7 Major Markets (7MM) expected to grow from USD 1,702 million in 2025 to USD 3,081 million by 2036. This growth is driven by rising diagnosis rates, expanding treatment pipelines, and increasing healthcare expenditure. The Follicular Lymphoma market research projects the market to expand at a CAGR of 6.8% through 2036, with leading geographies including the United States, EU4 countries (Germany, France, Italy, Spain), the United Kingdom, and Japan contributing significantly to this growth.
Explore the full Follicular Lymphoma Market report to uncover in-depth epidemiology, competitive intelligence, and treatment forecasts shaping the future of Follicular Lymphoma care.
Follicular Lymphoma Overview
Follicular lymphoma is a generally indolent, slow-growing B-cell lymphoproliferative disorder arising from transformed follicular center B cells. It is characterized by diffuse lymphadenopathy, bone marrow involvement, and splenomegaly, while extranodal involvement is less common. Cytopenias are relatively common, but constitutional symptoms such as fever, night sweats, and weight loss are uncommon in the absence of transformation to diffuse large B-cell lymphoma. Follicular lymphoma is typically not considered curable and is instead categorized as a chronic disease requiring long-term management and monitoring.
Follicular Lymphoma Diagnosis
Diagnosis of follicular lymphoma is established through histology from a biopsy of a lymph node or other affected tissue, with incisional biopsy preferred over needle biopsies to ensure adequate tissue for grading and transformation assessment. Immunohistochemical staining is positive in virtually all cases for CD19, CD20, CD10, monoclonal immunoglobulin, and cytoplasmic bcl-2 protein. The characteristic t(14;18) translocation involving IgH/bcl-2 genes is present in the overwhelming majority of cases. Staging workup includes CT scanning of the chest, abdomen, and pelvis, and PET scanning may be employed in localized disease or when transformation is suspected. Bone marrow aspiration and chromosomal analysis further support diagnosis, as the t(14;18) translocation is identified in the majority of patients.
Follicular Lymphoma Treatment
Treatment of follicular lymphoma is stage- and symptom-dependent:
- Observation is appropriate for asymptomatic patients with low-bulk disease and no cytopenias, as early treatment offers no overall survival advantage.
- Most patients requiring therapy receive chemoimmunotherapy, which has improved overall response rates, duration of response, and overall survival; maintenance rituximab provides additional benefit.
- Lenalidomide was non-inferior to chemoimmunotherapy in front-line studies and, combined with rituximab, was superior to rituximab alone in relapsed settings.
- Kinase inhibitors, stem cell transplantation (SCT), and CAR-T cell therapies are considered for recurrent disease.
- Early-stage localized disease may be managed with radiation therapy or surgical excision.
Follicular Lymphoma Epidemiology
The Follicular Lymphoma market insight is deeply informed by robust epidemiological data forecasted from 2022 to 2036, segmented by total diagnosed incidence, gender, age, stage, grade, and treated cases by line of therapy across the 7MM.
Key epidemiological findings include:
- Among the 7MM, the United States accounted for the highest number of Follicular Lymphoma cases in 2024, with nearly 17,000 cases, expected to increase through 2034.
- In 2024, the 60–80 age group recorded the highest incidence at approximately 9,000 cases, followed by individuals aged 40–59 with around 4,000 cases.
- Stage IV cases represented approximately 35% of total follicular lymphoma cases in 2024.
- The combined incidence across EU4 countries and the UK reached approximately 14,000 cases in 2024, with Germany recording the highest case count within this group.
Follicular Lymphoma Marketed Drugs
LUNSUMIO (mosunetuzumab): Roche
LUNSUMIO (mosunetuzumab) is a bispecific antibody therapy designed to treat adults with relapsed/refractory (R/R) follicular lymphoma after two or more prior lines of therapy. It binds to both T cells and B cells, activating the immune system to target and destroy cancerous B cells. The most significant associated risk is Cytokine Release Syndrome (CRS), a common and potentially life-threatening side effect.
- In December 2024, Chugai received regulatory approval for LUNSUMIO in Japan for intravenous infusion, enabling monotherapy for patients with at least two prior therapies.
- In December 2022, the FDA granted accelerated approval for adult R/R follicular lymphoma patients after two or more lines of systemic therapy.
- In June 2022, the European Commission granted conditional marketing authorization for adult R/R follicular lymphoma patients after two or more prior systemic therapies.
BRUKINSA (zanubrutinib): BeiGene
BRUKINSA (zanubrutinib) is a small-molecule Bruton’s tyrosine kinase (BTK) inhibitor approved for adult R/R follicular lymphoma patients in combination with obinutuzumab after two or more lines of systemic therapy. It is the first and only BTK inhibitor specifically indicated for follicular lymphoma, working by covalently binding to BTK and inhibiting B-cell signaling pathways involved in proliferation, adhesion, and migration.
- In March 2024, the FDA granted accelerated approval to BRUKINSA in combination with obinutuzumab for adult R/R follicular lymphoma after two or more lines of systemic therapy.
- In August 2022, BRUKINSA received orphan-drug designation from the US FDA for the treatment of follicular lymphoma.
Follicular Lymphoma Emerging Therapies
MONJUVI (tafasitamab): Incyte Corporation
MONJUVI (tafasitamab) is a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody that binds to CD19 on the surface of B cells, blocking activity and causing lysis through apoptosis, Antibody-dependent Cell-mediated Cytotoxicity (ADCC), and Antibody-dependent Cellular Phagocytosis (ADCP). MorphoSys licensed worldwide rights from Xencor, Inc. in 2010, and the molecule incorporates an XmAb-engineered Fc domain.
- In December 2024, Incyte presented late-breaking Phase III inMIND trial data at the ASH Annual Meeting, demonstrating that MONJUVI combined with lenalidomide and rituximab significantly improved Progression-free Survival (PFS) in R/R follicular lymphoma patients, meeting both the primary PFS endpoint and key secondary endpoints.
AZD0486: AstraZeneca
AZD0486 (formerly TNB-486) is a novel, IgG4 fully human CD19xCD3 bispecific T-cell engager (TCE) incorporating a low-affinity anti-CD3 moiety designed to reduce cytokine release while maintaining potent T-cell mediated cytotoxicity against malignant B cells. A silenced Fc prevents nonspecific binding and confers a long half-life suitable for intermittent dosing. The drug is currently in Phase III development for follicular lymphoma.
- In November 2024, at ASH 2024, AstraZeneca presented two oral presentations on AZD0486, with Phase I results demonstrating a 96% Overall Response Rate (ORR) and 85% Complete Response Rate (CRR) at doses of 2.4 mg and above in R/R follicular lymphoma patients.
Follicular Lymphoma Market Outlook
The Follicular Lymphoma market trends reflect a dynamic and rapidly evolving treatment landscape. Frontline therapy remains well established, with most patients achieving durable responses to chemoimmunotherapy (CIT). For localized disease, radiotherapy alone or in combination with immunochemotherapy remains a viable option.
Among currently approved therapies, GAZYVA/GAZYVARO (obinutuzumab) has become a cornerstone of frontline treatment, with demonstrated efficacy in both untreated and relapsed settings. RITUXAN (rituximab) and RITUXAN HYCELA remain among the most widely used agents, and the availability of rituximab biosimilars has improved accessibility. TAZVERIK (tazemetostat), an EZH2 inhibitor, adds a precision medicine approach for patients with specific mutations.
The recent approvals of EPKINLY/TEPKINLY (epcoritamab) and bispecific antibody platforms, alongside CAR-T cell therapies including KYMRIAH (tisagenlecleucel), YESCARTA (axicabtagene ciloleucel), BREYANZI (lisocabtagene maraleucel), and LUNSUMIO (mosunetuzumab), are ushering in a new era of immunotherapy-driven management. These agents are delivering promising and durable responses in R/R settings and are expected to redefine long-term remission strategies through the forecast period of 2026–2036.
The leading companies active in the Follicular Lymphoma space include Merck Sharp and Dohme, AstraZeneca, CRISPR Therapeutics, BeiGene, Nektar Therapeutics, NovalGen, Carna Biosciences, Allogene Therapeutics, Xynomic Pharmaceuticals, Bristol-Myers Squibb, Incyte Corporation, and others.
Gain exclusive access to Follicular Lymphoma Market insights, pipeline analysis, and strategic opportunities driving the evolution of Follicular Lymphoma treatment through 2036.
Conclusion
The Follicular Lymphoma market is poised for substantial expansion through 2036, driven by rising disease incidence, improved diagnostic capabilities, and rapid advancements in targeted and immunotherapy-based treatments. The emergence of bispecific antibodies, CAR-T therapies, kinase inhibitors, and precision medicines is transforming the management of relapsed and refractory disease while improving long-term patient outcomes. Increasing regulatory approvals and robust late-stage clinical pipelines further strengthen market growth prospects across the 7MM. With continuous innovation from leading pharmaceutical companies and growing healthcare investment, the global Follicular Lymphoma landscape is expected to witness significant therapeutic progress, enhanced accessibility, and sustained commercial growth in the coming decade.
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharmaceutical companies by providing comprehensive end-to-end solutions to improve their performance. It also offers healthcare consulting services that leverage market analysis to accelerate business growth and overcome challenges with practical approaches.
Media contact
Name: Abhishek kumar
E-mail:abhishek@delveinsight.com
